Joshua Hackel, MD
Sports Medicine · Gulf Breeze, FLNPI 1225020936
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (30.4%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Tenex Health Inc. at 43.8% of the total. Reporting peaked in 2021 at $3,484 and has fallen 75.8% since, to $842 in 2025.
Across 88 payments — averaging $107.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tenex Health Inc.$4K
- Trice Medical, Inc.$2K
- Curonix LLC$993
- Bioness Inc$447
- CGG Medical Inc$402
- Ferring Pharmaceuticals Inc.$384
- plus $730 from 10 others
What the payments were for
- Consulting fees$2,30024%
- Speaking & faculty fees$2,12523%
- Travel & lodging$1,69818%
- Food & beverage$2,87230%
- Entertainment$4475%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tenex Health Inc. | 8 | $4,135 |
| Trice Medical, Inc. | 8 | $2,352 |
| Curonix LLC | 18 | $993 |
| Bioness Inc | 2 | $447 |
| CGG Medical Inc | 4 | $402 |
| Ferring Pharmaceuticals Inc. | 22 | $384 |
| Bioventus LLC | 7 | $264 |
| Johnson & Johnson | 7 | $150 |
| Vertex | 3 | $63 |
| Avanos Medical | 2 | $60 |
| DJO, LLC | 1 | $39 |
| Pacira Pharmaceuticals Incorporated | 1 | $35 |
| Nalu Medical, Inc. | 2 | $32 |
| Si-bone, Inc. | 1 | $31 |
| SPR Therapeutics, Inc | 1 | $29 |
| Pacira Therapeutics, Inc. | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,443 in reported general payments places this provider in the 75th percentile of 402 sports medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 215 | $1,116 |
| Celecoxib | 34 | $501 |
| Diclofenac Sodium | 20 | $280 |
| Tramadol Hcl | 113 | $221 |
| Prednisone | 90 | $216 |
| Cephalexin | 20 | $199 |
| Meloxicam | 49 | $124 |
Paid to pharmacies, not to this prescriber.
Other sports medicine in Gulf Breeze
- Adam AnzGulf Breeze$354K
- Brett KindleGulf Breeze$33K
- Lee KaplanMiami$11.3M
- Patrick SmithNaples$2.9M
- Ryan SimovitchWest Palm Beach$1.1M
- Bruce LevyOrlando$816K
- Gautam YagnikMiami$440K
- Carl DilellaVero Beach$384K
- Stanton LongeneckerJacksonville$330K
- Luga PodestaNaples$206K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.